Skip to content
DataLookout
Menu

KeDANCT06090422

Ketamine for Combined Depression and Alcohol Use Disorder

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jul 1, 2027 to Jul 1, 2028 Show 4 more changesShow less
    • Eligibility criteria expanded, about 4 words
    • Study sites: 1 to 2
    • Secondary endpoints: details revised at 1 of 5 entries
    • Collaborators: 1 to 2
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 1, 2025 to Jan 20, 2025
    v4
  3. Notable Start date: Jan 1, 2024 to Jan 1, 2025
    • Primary endpoints: 5 to 1
    • Secondary endpoints: 3 to 5
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Depression
Timeframe: Within 3 days after final treatment session

Secondary (5)

Alcohol craving tonic
Alcohol craving phasic
Depression response/remission
Relapse risk
Time until relapse

Arms and interventions

Intervention groupExperimental

Ketamine, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)

Control groupActive comparator

Midazolam, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)

Drugs: Ketamine Hydrochloride, Midazolam Hydrochloride

Sites

2 sites in 1 country